NeuroSense Therapeutics (NASDAQ:NRSN) Stock Rating Upgraded by Wall Street Zen

NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other analysts also recently commented on NRSN. Zacks Research raised shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Noble Financial raised shares of NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Monday, December 22nd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NeuroSense Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.78 on Friday. The stock’s 50-day moving average is $0.98 and its 200 day moving average is $1.30. NeuroSense Therapeutics has a one year low of $0.68 and a one year high of $2.60.

Institutional Trading of NeuroSense Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics in the third quarter valued at approximately $26,000. Jane Street Group LLC bought a new position in NeuroSense Therapeutics during the 2nd quarter valued at $54,000. Finally, Squarepoint Ops LLC lifted its stake in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.